VivoSeq
Immunology

Mucositis

54

Pipeline Programs↗

2

Active Trials↗

22

Companies Involved↗

Mucositis is a moderately active landscape with 54 programs across 22 companies. The most active players are Merck & Co., Jazz Pharmaceuticals, Citius Pharmaceuticals, Inc.. 6 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

0/100

Mech. Concentration

24/100

Completion Rate

77/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1C

Citius Pharmaceuticals, Inc.

1 program

Phase 2A

Arbor Pharmaceuticals, Inc.

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Palifermin

Swedish Orphan Biovitrum

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Chlorhexidine

Dexcel Pharma Technologies Ltd.

Lyrica

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Traumeel S

Shaare Zedek Medical Center

Phase 14

Curcumin

Merck & Co.

Flurbiprofen

Pharmacia and Upjohn

Sativex

Jazz Pharmaceuticals

Fusilev

Acrotech Biopharma Inc.

Phase 220

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Ketamine

Aultman Health Foundation

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Chlorhexidine Gluconate

Medline Industries

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Phase 316

Glutamine

Sanofi

Gabapentin

Viatris Specialty LLC

Fentanyl

Cephalon

Morphine

Hikma Pharmaceuticals LLC

Fluoride

GSK

Approved6

Hydromorphone

Rhodes Pharmaceuticals, L.P.

Zinc

American Regent, Inc.

Amifostine

Legacy Health System

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Phenylephrine

Exela Pharma Sciences, LLC.

Analysis

Modality Breakdown

97%

Small molecule

61 of 63 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme23%

Small molecule leads; the ring shows all 63 classified programs, each share of the total. Modality classified for 100% of 64 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed36 · 63%
Unknown status8 · 14%
Terminated7 · 12%
Withdrawn4 · 7%
Active, not recruiting1 · 2%
Enrolling by invitation1 · 2%

Clinical Trials

Trial Activity

57 trials

Safety and Efficacy of N-Acetylcysteine Mouthwash in Prevention of Mucositis in HSCT Patients
Active, not recruiting·TTehran University of Medical Sciences·Phase 3·NCT07325383·106 enrolled
Progression and Resolution of Experimental Peri-implant Mucositis on Now Healthy Implant Sites That Were Previously Treated With or Without Implantoplasty: A Controlled Clinical Trial
Enrolling by invitation·UUniversity of Pittsburgh·Preclinical·NCT06063876·30 enrolled
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
Completed·MMedical College of Wisconsin·Phase 2·NCT04752384·20 enrolled
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
Completed·—·Phase 3·NCT03825887·80 enrolled
Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis
Completed·JJuravinski Cancer Centre Foundation·Phase 3·NCT00814359·67 enrolled
A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis
Completed·UUniversity of Oklahoma·Phase 1·NCT00584597·14 enrolled
Non-surgical Treatment of Peri-implant Mucositis
Completed·—·N/A·NCT03915665·74 enrolled
Early Use of Opioid in Radiation Mucositis
Completed·—·Phase 2·NCT02309437·200 enrolled
Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash
Completed·AAaron Cumpston, PharmD, BCOP·Phase 2·NCT01566448·30 enrolled
Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.
Completed·UUniversity Hospital, Angers·Phase 3·NCT04080622·100 enrolled
Local Anesthetic Treatment of Oral Pain in Patients With Mucositis
Completed·HHvidovre University Hospital·Phase 2·NCT02252926·70 enrolled
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis
Completed·UUniversidade Federal do Rio Grande do Norte·Phase 2·NCT02605382·37 enrolled
Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers
Completed·MMashhad University of Medical Sciences·Phase 2·NCT01375088·20 enrolled
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00003139·249 enrolled
Adjunctive Treatments for the Prevention of Radiotherapy-Induced Mucositis
Completed·—·N/A·NCT06117904·60 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)